sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Deferiprone

Medicine · Iron Chelator

Deferiprone

Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.

Medication guideLabel updated 2025-05-28

Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗

Boxed warning

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor regularly while on therapy. Interrupt deferiprone therapy if neutropenia develops. Interrupt deferiprone if infection develops, and monitor the ANC more frequently. Advise patients taking deferiprone to report immediately any symptoms indicative of infection. WARNING: AGRANULOCYTOSIS AND NEUTROPENIA See full prescribing information for complete boxed warning. Deferiprone can cause agranulocytosis that can lead to serious infections and death. Measure the absolute neutrophil count (ANC) before starting deferiprone and monitor regularly while on therapy.

Drug facts

Used for
Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.
How to take it
Take deferiprone tablets exactly as your healthcare provider tells you.

What it is used for

Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Deferiprone tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.

Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX ® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

The most important thing to know

Deferiprone tablets can cause serious side effects, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with deferiprone tablets and can become severe in some people.

Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death. Your healthcare provider will do a blood test before you start deferiprone tablets and regularly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves.

Your healthcare provider may temporarily stop treatment with deferiprone tablets if you develop neutropenia or infection. Stop taking deferiprone tablets and call your healthcare provider or get medical help right away if you develop any of these symptoms of infection: fever sore throat or mouth sores flu-like symptoms chills and severe shaking It is important for you to have your white blood cell count checked within 24 hours of developing symptoms of an infection to see if you have severe neutropenia (agranulocytosis).

Do not delay getting medical care if you are unable to reach your healthcare provider. See "

How to take it

Take deferiprone tablets exactly as your healthcare provider tells you. Your healthcare provider will prescribe deferiprone tablets based on your body weight. Your healthcare provider will check your body iron level during treatment with deferiprone tablets and may change your dose if needed. Your healthcare provider may also change your dose of deferiprone tablets if you have certain side effects.

Do not change your dose of deferiprone tablets unless your healthcare provider tells you to. There are 2 types of deferiprone tablets. Be sure you are taking the correct tablet and ask your healthcare provider if unsure. Deferiprone Tablets 1,000 mg 3 times each day Deferiprone Tablets 500 mg 3 times each day Take your first dose in the morning, the second dose at midday, and the third dose in the evening.

Take your first dose in the morning, the second dose at mid-day, and the third dose in the evening. Taking deferiprone tablets with meals may help reduce nausea. If you must take a medicine to treat indigestion (antacid), or supplements that contain iron, aluminum, or zinc during treatment with deferiprone tablets, allow at least 4 hours between taking deferiprone tablets and these products.

If you take too much deferiprone tablets, call your healthcare provider. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and then continue with your regular schedule. Do not try to catch-up or take 2 doses at the same time to make up for a missed dose. What are the possible side effects of deferiprone tablets?

Deferiprone tablets can cause serious side effects, including: Increased liver enzyme levels in your blood. Your healthcare provider should do blood tests to check your liver function before you start and then monthly during treatment with deferiprone tablets. Your healthcare provider may temporarily stop treatment with deferiprone tablets if you develop increased liver enzyme levels and they continue to be increased.

Decreased levels of zinc in your blood. Your healthcare provider will do blood tests to check your zinc levels before you start and during treatment with deferiprone tablets, and may prescribe a zinc supplement for you if your zinc levels are low. The most common side effects of deferiprone tablets in people with thalassemia include: nausea vomiting stomach-area (abdominal) pain joint pain abnormal liver function tests low white blood cells Deferiprone tablets may cause a change in urine color to reddish-brown.

This is not harmful and is expected during treatment with deferiprone tablets. These are not all of the possible side effects of deferiprone tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects, and when to stop

" for more information about side effects. What is deferiprone? Deferiprone is a prescription medicine used to treat iron overload from blood transfusions in adults with thalassemia syndromes when current iron removal (chelation) therapy does not work well enough. It is not known if deferiprone tablets is safe and effective to treat iron overload due to blood transfusions: in people with myelodysplastic syndrome or Diamond Blackfan anemia in children less than 8 years of age

Who should not take it

Do not take deferiprone tablets if you are allergic to deferiprone or any of the ingredients in deferiprone tablets. See the end of this Medication Guide for a complete list of ingredients in deferiprone tablets. Before taking deferiprone tablets, tell your healthcare provider about all of your medical conditions, including if you: have liver problems are pregnant or plan to become pregnant.

Deferiprone tablets can harm your unborn baby. You should avoid becoming pregnant during treatment with deferiprone tablets. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with deferiprone tablets. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with deferiprone tablets.

You should use effective birth control during treatment with deferiprone tablets and for at least 6 months after the last dose. Males with female partners who are able to become pregnant: You should use effective birth control during treatment with deferiprone tablets and for at least 3 months after the last dose. are breastfeeding or plan to breastfeed.

It is not known if deferiprone passes into your breast milk. Do not breastfeed during treatment with deferiprone tablets and for at least 2 weeks after the last dose. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Storing it

Deferiprone Tablets 1,000 mg 3 times each day Deferiprone Tablets 500 mg 3 times each day Store at room temperature between 68°F to 77°F (20°C to 25°C). Store in the original bottle and tightly closed to protect from moisture. Store at room temperature between 68°F to 77°F (20°C to 25°C). Keep deferiprone tablets and all medicines out of the reach of children.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Deferiprone; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/deferiprone

APA 7th

sofidex. (2026, August 2). Deferiprone. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/deferiprone

AMA 11th

Deferiprone. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/deferiprone

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.